NCT02853344View on ClinicalTrials.gov

Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427)

PHASE2CompletedINTERVENTIONAL

Enrollment

275

Participants

Timeline

Start Date

September 30, 2016

Primary Completion Date

February 5, 2021

Study Completion Date

April 1, 2022

Conditions

Renal Cell Carcinoma

Interventions

BIOLOGICAL

Pembrolizumab

IV infusion

All Listed Sponsors

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02853344 - Study of Pembrolizumab (MK-3475) Monotherapy in Locally Advanced/Metastatic Renal Cell Carcinoma (MK-3475-427/KEYNOTE-427) | Biotech Hunter | Biotech Hunter